Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Diabetic retinopathy Stories

2012-05-07 22:21:45

TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen Pharmaceutical Co., Ltd.?"Santen"?entered into a co-promotion agreement for EYLEA® (aflibercept) Injection in Japan. As previously announced, Bayer Yakuhin has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) for EYLEA for...

2012-05-07 11:02:46

Study proposals could reduce screening costs by around 25 percent Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually. The research is supported by funding from the National Institute for Health Research Peninsula Collaboration for...

2012-05-07 09:16:34

Nutriceutical offers hope to those facing blindness There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle and have become the standard of care for patients with the fast-progressive form of macular degeneration, they are not foolproof. For the first time researchers report that...

Image Credit: Photos.com
2012-05-02 08:50:45

Image Credit: Photos.com --- Connie K. Ho for RedOrbit.com Mark your calendars: May is Healthy Vision Month. Since 2003, the National Eye Institute (NEI) has promoted May with this national eye health observance. During Health Vision Month, NEI hopes to increase awareness about early diagnosis and treatment of vision loss. The NEI, under the National Institute of Health (NIH), helps develop the federal government´s research on the visual system and eye diseases. The NIH is...

2012-04-27 02:25:42

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina(TM). Ampio also received a notice of allowance of a similar patent...

2012-04-27 02:25:38

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse(TM) technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS). Glaucoma is the leading cause of adult irreversible blindness. It is estimated...

2012-04-10 09:10:30

A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that was previously demonstrated at 12 months was maintained through 24 months, according to a report published Online First by Archives of Ophthalmology, a JAMA Network publication. Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT) has...

2012-03-28 06:26:26

Positive recommendation based on treatment's efficacy and cost effectiveness DORVAL, Quebec, March 28, 2012 /PRNewswire/ - The Canadian Agency for Drugs and Technologies in Health (CADTH) has positively recommended to Canada's provincial and other publicly funded drug plans that they reimburse the Novartis Pharmaceuticals Canada Inc. ("Novartis") drug Lucentis* (ranibizumab) to treat vision loss resulting from diabetic macular edema (DME), one of the major causes of adult vision...

2012-03-19 02:24:40

GREENWOOD VILLAGE, Colo., March 19, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane(TM)( )completed two phase III studies, Ampion(TM)-completed proof of concept studies and Optina(TM)), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the...